<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>81</patient-age><report-id>PHHY2012CO113356</report-id><gender>female</gender><reactions><reaction>Urinary infections</reaction><reaction>Sugar high</reaction><reaction>High blood pressure</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>ACLASTA</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>TELMISARTAN</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>AMLODIPINE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>CLONIDINE</drug-name><manufacturer/><ingredients/></drug></drugs><outcomes/><country>Colombia</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053142_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211133938</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHHY2012CO113356</safetyreportid>
		<primarysourcecountry>CO</primarysourcecountry>
		<occurcountry>CO</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-10</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-12-05</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-05</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012CO113356</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportergivename>Martha</reportergivename>
			<reporterfamilyname>Camacho</reporterfamilyname>
			<reporterstreet>Diagonal 22 C 29 A 32</reporterstreet>
			<reportercity>BogotìŽ¡</reportercity>
			<reportercountry>CO</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>AAC</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19310605</patientbirthdate>
			<patientweight>50</patientweight>
			<patientheight>145</patientheight>
			<patientsex code="2">Female</patientsex>
			<reaction>
				<primarysourcereaction>Urinary infections</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Urinary tract infection</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Urinary tract infection</reactionmeddrapt>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201207</reactionstartdate>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Sugar high</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Blood sugar increased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Blood glucose increased</reactionmeddrapt>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201207</reactionstartdate>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>High blood pressure</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Blood pressure high</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Hypertension</reactionmeddrapt>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201207</reactionstartdate>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>ACLASTA</medicinalproduct>
				<obtaindrugcountry>CO</obtaindrugcountry>
				<drugauthorizationnumb>21-817</drugauthorizationnumb>
				<drugauthorizationcountry>CO</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugdosageform normalized="solution for injection">Solution For Injection</drugdosageform>
				<drugadministrationroute code="042">Intravenous (not otherwise specified)</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2011-09-15</drugstartdate>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ZOLEDRONATE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood glucose increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood glucose increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypertension</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypertension</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Urinary tract infection</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Urinary tract infection</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>TELMISARTAN</medicinalproduct>
				<obtaindrugcountry>CO</obtaindrugcountry>
				<drugauthorizationcountry>CO</drugauthorizationcountry>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>TELMISARTAN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>AMLODIPINE</medicinalproduct>
				<obtaindrugcountry>CO</obtaindrugcountry>
				<drugauthorizationcountry>CO</drugauthorizationcountry>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMLODIPINE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>CLONIDINE</medicinalproduct>
				<obtaindrugcountry>CO</obtaindrugcountry>
				<drugauthorizationcountry>CO</drugauthorizationcountry>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>CLONIDINE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012CO113356, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report from <Semaphore x="2352630" class="Occupation" value="Other Health Care Professional" score="1.00" ID="C53289">other health care professional </Semaphore>received via marketing program Aclasta V+S on 05 Dec 2012. This report refers to an 81-year old female patient. Concomitant medications included <Semaphore x="1251242" class="Medicine" value="telmisartan" score="0.49" ID="282222">telmisartan </Semaphore>(<Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">manufacturer </Semaphore>unknown), <Semaphore x="103656" class="Medicine" value="Amlodipine" score="0.49" ID="239933">amlodipine </Semaphore>(<Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">manufacturer </Semaphore>unknown) and <Semaphore x="382785" class="Medicine" value="Clonidine" score="0.49" ID="251862">clonidine </Semaphore>(<Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">manufacturer </Semaphore>unknown). The patient received an unspecified dose of Aclasta (<Semaphore x="1384774" class="Medicine" value="zoledronic acid" score="0.49" ID="274011">zoledronic <Semaphore x="2147465" class="Procedure" value="Lysergide Measurement" score="1.00" ID="C75354">acid</Semaphore></Semaphore>) one ampoule intravenous for <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of unknown indication on 15 Sep 2011. It was reported that in Jul 2012, the patient experienced <Semaphore x="2036573" class="Disease or Finding" value="Hypergonadotropic Hypogonadism" score="1.00" ID="C113348"><Semaphore x="2036545" class="Disease or Finding" value="Hyperglycemia" score="1.00" ID="C26797"><Semaphore x="3018504" class="MedDRA LLT" value="Hypertension" score="1.00" ID="10020772">high <Semaphore x="2036529" class="Disease or Finding" value="Hyperglycemia Artifact" score="1.00" ID="C87037">blood pressure</Semaphore>
         <Semaphore x="2038093" class="Disease or Finding" value="Hypertension" score="1.00" ID="C3117">
          <Semaphore x="2036573" class="Disease or Finding" value="Hypergonadotropic Hypogonadism" score="1.00" ID="C113348">
           <Semaphore x="2036545" class="Disease or Finding" value="Hyperglycemia" score="1.00" ID="C26797">
            <Semaphore x="2036529" class="Disease or Finding" value="Hyperglycemia Artifact" score="1.00" ID="C87037">, </Semaphore></Semaphore></Semaphore></Semaphore>
         <Semaphore x="2036573" class="Disease or Finding" value="Hypergonadotropic Hypogonadism" score="1.00" ID="C113348">
          <Semaphore x="2036545" class="Disease or Finding" value="Hyperglycemia" score="1.00" ID="C26797">
           <Semaphore x="2979967" class="MedDRA LLT" value="Glucose urine present" score="1.00" ID="10018478">sugar </Semaphore>
           </Semaphore>
          </Semaphore>
         <Semaphore x="2979967" class="MedDRA LLT" value="Glucose urine present" score="1.00" ID="10018478">high </Semaphore></Semaphore>
      <Semaphore x="2038093" class="Disease or Finding" value="Hypertension" score="1.00" ID="C3117">
       <Semaphore x="3018504" class="MedDRA LLT" value="Hypertension" score="1.00" ID="10020772">
        </Semaphore></Semaphore></Semaphore>
     <Semaphore x="2038093" class="Disease or Finding" value="Hypertension" score="1.00" ID="C3117">
      <Semaphore x="3018504" class="MedDRA LLT" value="Hypertension" score="1.00" ID="10020772">
       </Semaphore></Semaphore></Semaphore>
    <Semaphore x="2038093" class="Disease or Finding" value="Hypertension" score="1.00" ID="C3117">
     <Semaphore x="3018504" class="MedDRA LLT" value="Hypertension" score="1.00" ID="10020772">
      </Semaphore></Semaphore>
    <Semaphore x="3018504" class="MedDRA LLT" value="Hypertension" score="1.00" ID="10020772">
     </Semaphore>
    <Semaphore x="2979967" class="MedDRA LLT" value="Glucose urine present" score="1.00" ID="10018478">and <Semaphore x="2671993" class="AnatomicStructure" value="Urinary System" score="1.00" ID="C12413">urinary </Semaphore></Semaphore>
    <Semaphore x="3299128" class="MedDRA LLT" value="Urinary tract infection" score="1.00" ID="10046571">infections</Semaphore>. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome</Semaphore>, seriousness and causality of the events were not reported.</narrativeincludeclinical>
				<sendercomment>Based on review of available reported data does not allow for a proper causality assessment. Reported events (urinary tract infection and blood glucose increased) are not assessable. There is a reasonable possibility of causal relationship for the event (hypertension).</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>